These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25261632)

  • 1. Is target validation all we need?
    Frigault MM; Barrett JC
    Curr Opin Pharmacol; 2014 Aug; 17():81-6. PubMed ID: 25261632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical biology approaches to target validation in cancer.
    Blagg J; Workman P
    Curr Opin Pharmacol; 2014 Aug; 17():87-100. PubMed ID: 25175311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recently targeted kinases and their inhibitors-the path to clinical trials.
    Knapp S; Sundström M
    Curr Opin Pharmacol; 2014 Aug; 17():58-63. PubMed ID: 25113945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 5. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development and potential clinical utility of biomarkers for HDAC inhibitors.
    Shi B; Xu W
    Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path to oncology drug target validation: an industry perspective.
    Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
    Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology and prostate cancer therapeutics: from biology to bedside.
    Rodrigues DN; Butler LM; Estelles DL; de Bono JS
    J Pathol; 2014 Jan; 232(2):178-84. PubMed ID: 24108540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
    Li SN; Li HQ
    Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the outcomes: developing cancer therapeutics.
    Utku N
    Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.